Hims & Hers Pulls Copycat Wegovy Pill as Novo Nordisk Jumps
Hims & Hers Pulls Copycat Wegovy Pill as Novo Nordisk Jumps
Hims & Hers abandons its cheaper Wegovy copy after legal threats from Novo Nordisk and U.S. authorities; Novo Nordisk climbs as the battle over patent and safety intensifies.
In a high-stakes turn in the weight‑loss drug race, Hims & Hers has pulled its cheaper compounded version of Wegovy after facing legal threats from Novo Nordisk and U.S. health authorities. The move comes after intense pushback to the copycat pill, which aimed to offer a lower-cost option by reformulating the medication. Investors reacted to the development, with Hims & Hers' stock falling about 14% after the announcement, while Novo Nordisk rose around 8% as investors weighed the potential implications for the weight‑loss drug market.
Novo Nordisk has sued to permanently block Hims from selling compounded Wegovy‑like products and to recover damages, arguing patent infringement and concerns about safety and efficacy. The court action seeks to halt the sale of the copycat product altogether and underscores the strong IP protections surrounding a high-demand therapy. The move also comes amid broader regulatory scrutiny of cheaper alternatives to blockbuster biologics, complicating any quick path back for a similar strategy from Hims & Hers.
The case highlights the high-stakes dynamics of a market where demand for weight‑loss therapies continues to surge and where patent protections are closely guarded. Analysts say a court ruling could influence other firms contemplating copycat attempts. For now, the immediate market takeaway is clear: Novo Nordisk is higher on the news, while Hims & Hers retreats from its foray into Wegovy alternatives. What happens next will hinge on legal proceedings and regulatory signals, with patients and doctors watching closely as the industry navigates safety, efficacy, and access in a rapidly evolving field.
